Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Trial of Anti-IL-20 (109-0012) 100 mg/Vial in Psoriatic Subjects, Followed by an Expansion Phase

NCT01261767 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01261767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01261767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Trial of Anti-IL-20 (109-0012) 100 mg/Vial in Psoriatic Subjects, Followed by an Expansion Phase
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2008
Completion date
January 31, 2011
Enrollment
55 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation, psoriasis